Nama's AI scorecard currently rates InnovAge Hold (5.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is INNV's P/E ratio?

InnovAge trades at a trailing price-to-earnings ratio of 16.6.

When does INNV report earnings?

InnovAge's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $0.09.

What is the INNV price target?

The median analyst price target from 2 analysts is $12.00, with a range of $10.00 – $14.00.

Is INNV Shariah compliant?

Nama's AAOIFI-style screen reads InnovAge as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

InnovAge (INNV)

Healthcare · Medical Care Facilities · NASDAQ

InnovAge (INNV) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.22B, a trailing price-to-earnings ratio of 16.6 and a free-cash-flow yield of -3.7%. Over the most recent reported fiscal year, revenue grew 11.0%. Nama's AI scorecard rates it Hold, 5.7 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 5.7/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +87.1% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-29.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.22B
Trailing P/E	16.6
Price / book	5.2
Price / sales	1.2
FCF yield	-3.7%
Dividend yield	—
Gross margin	23.0%
Operating margin	0.6%
Net margin	-0.3%
Revenue growth (YoY)	+11.0%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

INNV earnings

Next report: Feb 2, 2027 (Q2 2027, EPS estimate $0.09). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q1 2027	Nov 3, 2026	$0.17	$0.09	+88.9%	$264.76M
Q4 2026	Sep 8, 2026	$0.10	$0.08	+25.0%	$261.95M
Q3 2026	May 5, 2026	$0.17	$0.05	+240.0%	$251.94M
Q2 2026	Feb 3, 2026	$0.10	$0.04	+150.0%	$239.71M

INNV analyst price target

Median target $12.00 from 2 analysts, ranging $10.00 – $14.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live INNV data on Nama Insights →

INNV FAQ

Is INNV a buy?: Nama's AI scorecard currently rates InnovAge Hold (5.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is INNV's P/E ratio?: InnovAge trades at a trailing price-to-earnings ratio of 16.6.
When does INNV report earnings?: InnovAge's next scheduled report is on Feb 2, 2027. Analysts expect EPS of $0.09.
What is the INNV price target?: The median analyst price target from 2 analysts is $12.00, with a range of $10.00 – $14.00.
Is INNV Shariah compliant?: Nama's AAOIFI-style screen reads InnovAge as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.